Wnt/β-catenin expression does not correlate with serum alkaline phosphatase concentration in canine osteosarcoma patients

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Piskun, Caroline M ^a   Muthuswamy, Anantharaman ^a   Huelsmeyer, Michael K ^a   Thompson, Victoria ^a   Stein, Timothy J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; WNT PROTEIN; LUCIFERASE; TISSUE EXTRACT;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANIMAL DISEASE; BLOOD; CELL NUCLEUS; DOG; DOG DISEASE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN TRANSPORT; REPORTER GENE; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ALKALINE PHOSPHATASE; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; IMMUNOHISTOCHEMISTRY; LUCIFERASES; OSTEOSARCOMA; PROTEIN TRANSPORT; TISSUE EXTRACTS; WNT SIGNALING PATHWAY;

EID: 80053993085     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026106     Document Type: Article

References (36)

1. Mirabello L, Troisi RJ, Savage SA, (2009) International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125: 229-234.
2. Mirabello L, Troisi RJ, Savage SA, (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
3. Gorlick R, Khanna C, (2010) Osteosarcoma. J Bone Miner Res 25: 683-691.
4. Morello E, Martano M, Buracco P, (2011) Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma. Vet J 189: 268-277.
5. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, et al. (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10: 625.
6. Liptak JM, Dernell WS, Ehrhart NP, Withrow SJ, (2004) Canine appendicular osteosarcoma: diagnosis and palliative treatment. Compendium of Continuing Education for the Practicing Veterinarian 26: 172-183.
7. Dernell WS, Ehrhart NP, Straw RC, Vail DM, (2007) Tumors of the skeletal system. In: Withrow SJ, Vail DM, editors. Withrow and MacEwen's Small Animal Oncology St. Louis, MO Saunders, Elsevier pp. 540-582.
8. Spodnick GJ, Berg RJ, Rand WM, Schelling SH, Couto G, et al. (1992) Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 200: 995-999.
9. Phillips B, Powers BE, Dernell WS, Straw RC, Khanna C, et al. (2009) Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 45: 33-38.
10. Ehrhart NP, Dernell WS, Hoffmann WE, Weigel RM, Powers BE, et al. (1998) Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 213: 1002-1006.
11. Garzotto CK, Berg J, Hoffmann WE, Rand WM, (2000) Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Int Med 14: 587-592.
12. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, et al. (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Cancer 106: 1154-1161.
13. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790.
14. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S, (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18: 1842-1853.
15. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
16. Grigoryan T, Wend P, Klaus A, Birchmeier W, (2008) Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 22: 2308-41.
17. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, et al. (2005) Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132: 49-60.
18. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, et al. (2007) Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25: 371-379.
19. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, et al. (2002) Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342.
20. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, et al. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20: 525-529.
21. Guo Y, Rubin EM, Xie J, Zi X, Hoang BH, (2008) Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 466: 2039-2045.
22. Rubin EM, Guo Y, Tu K, Xie J, Zi X, et al. (2010) Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9: 731-741.
23. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, et al. (2010) Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220: 24-33.
24. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, et al. (2007) Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117: 3248-3257.
25. MacDonald BT, Tamai K, He X, (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
26. Henthorn PS, Millán JL, Leboy P, (1999) Acid and Alkaline Phosphatases. In: Seibel MJ, Robins SP, Bilezikian JP, editors. Dynamics of Bone and Cartilage Metabolism San Diego, CA Academic Press pp. 130-134.
27. Matsuzaki E, Takahashi-Yanaga F, Miwa Y, Hirata M, Watanabe Y, et al. (2006) Differentiation-inducing factor-1 alters canonical Wnt signaling and suppresses alkaline phosphatase expression in osteoblast-like cell lines. J Bone Miner Res 21: 1307-1316.
28. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, et al. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026.
29. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R, (1997) Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804.
30. Polakis P, (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
31. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, et al. (2005) Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280: 2498-2502.
32. Fukuda T, Kokabu S, Ohte S, Sasanuma H, Kanomata K, et al. (2010) Canonical Wnts and BMPs cooperatively induce osteoblastic differentiation through a GSK3beta-dependent and beta-catenin-independent mechanism. Differentiation 80: 46-52.
33. Wang L, Zhang X, Guo Y, Chen X, Li R, et al. (2010) Involvement of BMPs/Smad signaling pathway in mechanical response in osteoblasts. Cell Physiol Biochem 26: 1093-1102.
34. Yan Y, Tang D, Chen M, Huang J, Xie R, et al. (2009) Axin2 controls bone remodeling through the beta-catenin-BMP signaling pathway in adult mice. J Cell Sci 122: 3566-3578.
35. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
36. Stein TJ, Holmes KE, Muthuswamy A, Thompson V, Huelsmeyer MK, (2011) Characterization of beta-catenin expression in canine osteosarcoma. Vet Comp Oncol 9: 65-73.